Anti-CD4 antibody [EPR19514] (Ab183685)
CD4, T-cell surface glycoprotein CD4, T-cell differentiation antigen L3T4, T-cell surface antigen T4/Leu-3, Cd4
用户验证的应用
推荐稀释比例
- IHC-P1/1000 Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- WB1/1000
- IP1/40
- IHC-Fr1/200
详细信息
背景信息
Anti-CD4 antibody [EPR19514] (ab183685) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-Fr IHC-P, IP and WB. Anti-CD4 antibody [EPR19514] (ab183685) was first used in a scientific publication in 2016 and has been cited over 351 times in peer reviewed journals. It's performance in IHC in mouse samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-CD4 antibody [EPR19514] (ab183685) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-CD4 antibody [EPR19514] (ab183685) has 20 independent reviews from customers. Anti-CD4 antibody [EPR19514] (ab183685) specifically detects CD4 (UniProt ID: P06332; Molecular weight: 49kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR19514 - ab221775. Antibody clone EPR19514 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 647, Alexa Fluor ® 488, Alexa Fluor ® 555 ( ab225310, ab277275, ab313727 ). IL-4 plays a role in conditions like systemic lupus erythematosus (SLE) and multiple sclerosis, where it influences immune responses and inflammation. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.
文献引用 (615)
A biosafe mouse model for SARS-CoV-2 infection that more realistically simulates COVID-19 symptoms.
一种生物安全的SARS-CoV-2感染小鼠模型，能够更真实地模拟COVID-19症状。
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth.
靶向巨噬细胞的CAR-T细胞能够重置和重编程肿瘤微环境，并控制转移性癌症的生长。
Tumour-infiltrating microplastics disrupt the JAK-STAT-microbiota axis to promote immunotherapy resistance in colorectal cancer.
肿瘤浸润性微塑料会破坏 JAK-STAT-微生物群轴，从而促进结直肠癌的免疫治疗耐药性。
Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression.
神经刺激胃癌与第 3 组固有淋巴细胞之间的相互作用，从而增强免疫抑制。
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.
抗 CSF-1R 疗法与免疫化疗相结合，可协调适应性免疫反应，以消除富含巨噬细胞的三阴性乳腺癌。
FAPα(+) Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence.
FAPα(+)巨噬细胞通过PD-L1和T细胞衰老的双重调控，在多发性骨髓瘤中协调免疫逃逸。
Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3.
利用新型高亲和力抗体选择性靶向 B7-H3 的 4Ig 同工型，通过 β-放射性配体疗法进行抗癌免疫启动。
MiR-1290 in natural killer cell derived extracellular vesicles: a pathogenic mediator of lupus nephritis and therapeutic target for th17 regulation.
自然杀伤细胞衍生的细胞外囊泡中的 miR-1290：狼疮性肾炎的致病介质和 th17 调控的治疗靶点。
Pyruvate kinase muscle 2 (PKM2) promotes CD4 T cell survival by regulating pyruvate oxidation during homeostasis and expansion.
丙酮酸激酶肌肉 2 (PKM2) 通过在稳态和扩增过程中调节丙酮酸氧化来促进 CD4 T 细胞存活。
- 1
- 2
- 3
- 4
- 5
- 6
- 62